Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 3/20 | 0.54 |
| ▸ | RORC | P51449 | 16/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338647 | 0.86 | BDKRB2 (0.46) | BDKRB2RORCPOLB | |
| SCHEMBL1560922 | 0.85 | BDKRB2 (0.55) | BDKRB2RORCPOLB | |
| SCHEMBL2638880 | 0.84 | RORC (0.55) | BDKRB2RORC | |
| SCHEMBL1772938 | 0.84 | BDKRB2 (0.75) | BDKRB2RORC | |
| SCHEMBL6442652 | 0.84 | BDKRB2 (0.75) | BDKRB2RORC | |
| Hydrochloric Acid SCHEMBL8182811 | 0.83 | BDKRB2 (0.74) | BDKRB2RORC | |
| Hydrochloric Acid SCHEMBL8182794 | 0.83 | BDKRB2 (0.74) | BDKRB2RORC | |
| SCHEMBL8443100 | 0.83 | BDKRB2 (0.73) | BDKRB2RORC | |
| SCHEMBL8443103 | 0.83 | BDKRB2 (0.73) | BDKRB2RORC | |
| SCHEMBL8183485 | 0.80 | BDKRB2 (0.66) | BDKRB2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303268-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | LUSO FARMACO INST (IT) | 2012-06-20 | — | — | EP | claimed |
| EP-2222275-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | LUSO FARMACO INST (IT) | 2011-10-19 | — | — | EP | claimed |
| US-20110112011-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2011-05-12 | — | — | US | claimed |
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-11-18 | — | — | US | claimed |
| EP-2222275-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2009065507-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2009-05-28 | — | — | WO | claimed |
| US-9101627-B2 | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2015-08-11 | — | — | US | disclosed |
| EP-2222275-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | LUSO FARMACO INST (IT) | 2011-10-19 | — | — | EP | disclosed |
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2222275-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | Istituto Luso Farmaco d'Italia S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009065507-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112011-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE | BDKRB2, PTGER2, PTGER1 | BDKRB2 1/4885RORC 945/4885POLB 1538/4885 |
| US-20100292156-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF | BDKRB2, BDKRB1, HCAR2 | BDKRB2 1/4885RORC 3493/4885POLB 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.